Biotricity Receives Health Canada Clearance for Biotres
- None.
- None.
Entering the Canadian Cardiology Devices market, valued at US$1.56 billion, represents a significant strategic move for Biotricity, particularly given the context of cardiovascular diseases' economic burden in Canada. The growth potential in this sector is underscored by the rising prevalence of heart diseases, which affects approximately 8.33% of Canadian adults and has led to substantial hospitalizations over the past decade. Biotricity's expansion is timely, as the demand for innovative healthcare solutions is on an upward trajectory, driven by an aging population and an increase in chronic health conditions.
The approval of Biotres by Health Canada not only enables Biotricity to address a large patient population but also aligns with the global trend towards wearable healthcare technology. The projected 18% growth in the wearable technology market, with healthcare wearables expected to reach US$30.1 billion by 2026, suggests a favorable environment for Biotricity's product offerings. The company's focus on cardiac monitoring devices and remote monitoring platforms taps into the digital treatment and care market in Canada, which is anticipated to grow at 9% annually. This positions Biotricity at the vanguard of a transformative wave in patient care, potentially leading to enhanced outcomes and improved quality of life for individuals with cardiovascular conditions.
The Health Canada approval of Biotricity's flagship product, Biotres, signifies an important development in the management of cardiovascular disease (CVD), the leading cause of death globally. Biotricity's diagnostic solutions are designed to empower patients to proactively manage their heart health, which is critical given that studies suggest up to 80% of premature heart attacks and strokes could be prevented with timely intervention. The high readmission rates for cardiovascular complications in Canada highlight the need for improved monitoring and patient engagement in managing their health.
Biotricity's technology, which offers precise cardiac monitoring and a remote monitoring platform, could potentially reduce hospital readmissions and healthcare costs by providing patients with actionable measures tailored to their specific needs. This could lead to a paradigm shift in how CVD is managed, emphasizing prevention and early intervention. The company's commitment to innovation in this space is crucial as it could drive advancements in the treatment and care of CVD, ultimately leading to better patient outcomes and reduced economic strain on the healthcare system.
Biotricity's entry into the Canadian Cardiology Devices market is a strategically important decision from an investment perspective. The company's ability to gain Health Canada approval indicates a robust regulatory strategy and opens the door to a market with a substantial economic footprint. Cardiovascular disease costs Canada US$21.2 billion annually, representing a significant portion of healthcare expenses. Biotricity's market entry could potentially capture a share of this expenditure by offering cost-effective and innovative solutions.
Investors should note the potential for increased revenue streams for Biotricity as it taps into the growing wearable healthcare technology market. The company's expansion into Canada could serve as a catalyst for further growth and market penetration, especially considering the projected increase in the digital treatment and care market. However, investors should also consider the competitive landscape and the challenges associated with market adoption and penetration. Biotricity's future financial performance will depend on its ability to effectively commercialize its products and achieve market acceptance amidst potential competitors in the cardiology devices space.
Well Positioned to Enter US
REDWOOD CITY, CA / ACCESSWIRE / February 29, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, proudly announced its Health Canada approval for expansion into the US
Biotricity's mission to develop innovative diagnostic solutions that engage and empower individuals to take control of their health starts with the deadliest chronic disease and one of healthcare's largest cost drivers: cardiovascular disease. Health Canada approval of Biotres, Biotricity's flagship product, is a critical step in the Company's quest to address the needs of more than 2.4 million Canadians living with heart disease and related conditions. This milestone achievement underscores Biotricity's dedication to reshaping healthcare through innovation.
"We are thrilled to bring our cutting-edge health solutions to Canada to play a significant role in enhancing the well-being of millions of Canadians," said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO. "Our mission is to empower individuals with the tools and support needed to proactively manage their cardiovascular health and enjoy healthier lives."
Cardiovascular disease remains one of the most significant health issues in Canada, affecting approximately 1 in 12 adults and leading to more than 2.6 million hospitalizations in the past decade. Alarmingly,
As the global wearable technology market gears up for an impressive
To discover more about Biotricity, visit www.biotricity.com today.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
Investor Relations
Biotricity Investor Relations
Investors@biotricity.com
SOURCE: Biotricity, Inc.
View the original press release on accesswire.com
